Exicure, Inc. (NASDAQ:XCUR) Sees Large Decline in Short Interest

Exicure, Inc. (NASDAQ:XCUR) was the target of a large decrease in short interest in the month of October. As of October 15th, there was short interest totalling 18,000 shares, a decrease of 67.8% from the September 30th total of 55,900 shares. Based on an average trading volume of 1,350,000 shares, the short-interest ratio is presently 0.0 days. Approximately 2.7% of the shares of the stock are short sold.

Exicure Stock Performance

Shares of NASDAQ XCUR traded up $0.05 during trading on Friday, hitting $2.38. The company had a trading volume of 381 shares, compared to its average volume of 487,682. The business’s 50-day moving average is $2.15 and its 200 day moving average is $1.04. The company has a market cap of $4.12 million, a P/E ratio of -0.52 and a beta of 1.28. Exicure has a 52 week low of $1.44 and a 52 week high of $6.00.

Exicure (NASDAQ:XCUR) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.07) earnings per share (EPS) for the quarter.

Insider Buying and Selling

In other news, major shareholder Co. Ltd. Dgp acquired 237,223 shares of the company’s stock in a transaction dated Thursday, September 12th. The stock was acquired at an average cost of $3.00 per share, for a total transaction of $711,669.00. Following the acquisition, the insider now directly owns 849,223 shares in the company, valued at approximately $2,547,669. This represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 3.90% of the company’s stock.

Exicure Company Profile

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.